IN RESPONSE TO AN INCREASE in functional demand, striated muscle undergoes a phenotypic adaptation characterized by a compensatory increase in mass with an alteration in contractile and metabolic properties of the cell (3) . Studies on the molecular mechanisms underlying growth factor-induced skeletal muscle hypertrophy have elucidated various prohypertrophic signaling molecules. However, little is known regarding potential negative regulators of the adaptational circuitry in response to insulin-like growth factor I (IGF-I)-stimulated muscle hypertrophy.
IGF-I is capable of activating many signal transduction pathways; however, recent data suggest that specific activation by IGF-I of the phosphatidylinositol 3Ј-kinase (PI3Ј-kinase) pathway significantly contributes to muscle hypertrophy (2) . IGF-I binds to the IGF-I receptor with high affinity, and this binding of IGF-I to its specific receptor ultimately leads to activation of the 85-kDa regulatory subunit of PI3Ј-kinase. Activation of PI3Ј-kinase induces the activation of protein kinase B (PKB or Akt) by way of phosphorylation of specific serine/threonine residues. Bodine et al. (2) suggested that activation of Akt is a major contributor of muscle hypertrophy process. Furthermore, a downstream target of Akt is a signaling protein termed glycogen synthase kinase-3␤ (GSK-3␤). Akt reduces GSK-3␤ kinase activity through specific phosphorylation of Ser 9 (7) . Decreases in activity (2) and increases in phosphorylation (2; unpublished observations) of GSK-3␤ occur in overloaded skeletal muscle in animals. Although the importance of the inhibition of GSK-3␤ is not completely understood, it appears that the reduction in GSK-3␤ kinase activity affects the activity of various transcription factors and global protein synthesis (11) . Obviously, if GSK-3␤ can impact both the regulation of transcription factor activation and protein synthesis, then it is very possible that GSK-3␤ could play an important role in skeletal muscle hypertrophy.
Recent data have implicated a role for GSK-3␤ as a negative regulator of cardiac muscle hypertrophy (1, 6, 10) . For example, inactivation of GSK-3␤ (phosphorylation of Ser 9 ) appears to be requisite for transcriptional activation of the atrial natriuretic factor (ANF) gene, an established marker of cardiac hypertrophy (10) . Furthermore, the regulation of cardiac hypertrophy-responsive gene expression is mediated via the modulation by GSK-3␤ of the NFAT (nuclear factors of activated T cells) and GATA family of transcription factors (6) . In addition, Rommel et al. (12) found that inactivation of GSK-3␤ significantly contributed to skeletal muscle hypertrophy.
Recent evidence points to an important role of GSK-3␤ in the IGF-I-stimulated skeletal muscle hypertrophy through the PI3Ј-kinase/Akt signaling cascades (12) . In the current study, we undertook a more detailed examination of the role of GSK-3␤ as a nega-tive regulator of skeletal muscle hypertrophy. We hypothesized that inhibiting GSK-3␤ activity through IGF-I exposure would increase the activity of an NFAT-inducible reporter gene.
METHODS

Materials.
Recombinant human IGF-I was purchased from Austral Biologicals (San Ramon, CA). The PI3Ј-kinase inhibitors LY-294002 and wortmannin were from Calbiochem (San Diego, CA) and Sigma (St. Louis, MO), respectively. All antibodies were purchased from Cell Signaling Technology (Beverly, MA) unless otherwise indicated: phospho-GSK-3␤ (Ser 9 ) rabbit polyclonal antibody raised against human phospho-GSK-3␤ Ser 9 peptide (1:1,000 dilution); GSK-3␤ mouse monoclonal antibody raised against amino acids 1-160 of rat GSK-3␤ (1:2,500 dilution; BD Transduction Laboratories, Lexington, KY); phospho-Akt (Ser 473 ) rabbit polyclonal antibody raised against mouse phospho-Ser 473 Akt peptide (1:1,000 dilution); and Akt rabbit polyclonal antibody raised against amino acids 466-479 of mouse Akt (1:300 dilution). pGSK-3␤A9 (cGSK-3␤) was a gift from James R. Woodgett (University of Toronto, Canada) (15) .
Cell culture. All cell culture experiments were performed by using C 2C12 skeletal muscle myoblasts (ATCC), maintained at 37°C and 10% CO2, in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Rockville, MD) supplemented with 1% penicillin-streptomycin antibiotic. Myoblasts were maintained at a subconfluent seeding density in growth medium; DMEM was supplemented with 20% fetal bovine serum (FBS). Differentiation into myotubes was induced by transferring myoblasts into differentiation medium (DM) consisting of DMEM with 2% horse serum. IGF-I and/or LiCl was added to the medium at the same time as the medium was changed to DM according to the previously described techniques of Semsarian et al. (13) . Medium was changed every 24 h to ensure maintenance of optimal concentrations of IGF-I and LiCl. Cultures were maintained in supplemented or nonsupplemented DM for various indicated time points between 1 min and 5 days.
Myotube staining and area calculation. Myotubes were stained after 5 days in DM by using a modified Wright stain with minor modifications to the manufacturer's recommendations (Sigma). Briefly, after aspiration of the DM, the culture plates were gently washed twice with ice-cold 1ϫ PBS. Next, the cells were fixed in 10% methanol for 15 min and stained with Wright solution for 2 min. The myotubes were then visualized by using a microscope (Olympus BH-2) and a SPOT Insight imaging color camera (Diagnostic Instruments). The image system was calibrated by using a micrometer at each magnification. Myotube area was quantified according to the previously described techniques of Semsarian et al. (13, 14) at ϫ10 magnification. The area of the myotubes was quantified by using SPOT Imaging software (Diagnostic Instruments). The area of each myotube is expressed in square micrometers. The individual area of 100 total myotubes was quantified from multiple separate microscope fields on three separate culture plates. The myotubes chosen were only those for which the entire outline (i.e., sarcolemma) could be clearly visualized within the microscope field. Smaller myotubes were not ignored if it was possible to visualize the entire myotube.
Transient transfection and reporter gene assays. Transient transfections were performed by using the Lipofectamine Plus reagent (Life Technologies) in accordance with the manufacturer's specifications. Briefly, the transfections were carried out in 24-well tissue culture plates (3 ϫ 10 4 cells/well) with a total of 0.4 g of DNA per transfection in serum-free DMEM. All assays were performed by using equimolar ratios of DNA, and the total amount of DNA per transfection was adjusted by using the pUC19 empty vector. Three hours after the transfection, the culture medium was changed to DMEM supplemented with 10% FBS overnight. The myoblasts were then washed twice with sterile PBS and subsequently received 2% horse serum medium supplemented with IGF-I and/or LiCl for an additional 18 h. The percent FBS used in the transfection experiments was intentionally reduced to minimize background NFAT-luciferase (NFAT-Luc) expression vector stimulation by endogenous serum growth factors. In those cultures in which LiCl was in the medium, cells were preconditioned in LiCl (10 mM) for 2 h before the onset of the experiment, which then remained present during the entire experiment. At the end of the incubation period, the cells were lysed with Reporter Lysis Buffer (Promega, Madison, WI), and luciferase activities were measured with the DualLuciferase Reporter Assay system (Promega) according to the manufacturer's recommendations. Each sample was cotransfected with 0.4 g of pRL-null (Promega) control reporter vector expressing Renilla luciferase, which was found to be optimum (data not shown). The pRL-null Renilla luciferase values obtained ranged from 737 to 1,413 relative light units across all conditions. In addition, cells that were not transfected with any reporter constructs exhibited minimal luciferase values of Ͻ100 relative light units. NFAT reporter firefly luciferase values were divided by pRL Renilla luciferase values to normalize for differences in transfection efficiency.
Immunoblotting analysis. For cell culture experiments, myoblasts were grown on 100-mm plates and scraped with the use of 400 l of lysis buffer [50 mM HEPES, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 2 mM MgCl 2, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 10 mM Na4P2O7, 100 mM NaF, 25 mM ␤-glycerophosphate, 1 mM Na4VO4, 1 mM dithiothreitol (DTT), 10 g/ml leupeptin, 10 g/ml aprotinin, 10 g/ml pepstatin, 10 g/ml tosyl-L-phenylalanine chloromethyl ketone, 10 g/ml N ␣ -p-tosyl-L-lysine chloromethyl ketone, 0.1 M okadaic acid, 1 mM benzamidine, and 2 mM Pefabloc SC Plus]. The scraped cells were lysed by rotation for 30 min at 4°C. Protein concentrations were determined by standard Bradford assay (Bio-Rad), and equal amounts (25 g) were fractionated by SDS-PAGE on a 10% gel. The samples were electrophoretically transferred to a nitrocellulose membrane in transfer buffer containing 25 mM Tris ⅐ HCl (pH 8.3), 192 mM glycine, and 20% (vol/vol) methanol. Membranes were stained with Ponceau S (Sigma) to verify equal loading between lanes and subsequently blocked in 5% nonfat dry milk/0.05% (vol/vol) Tween 20 for 1 h at room temperature. The filter was then incubated in primary antibody for 12 h at 4°C and washed six times (5 min each) with TBS-T (25 mM Tris-base, pH 8.3, 150 mM NaCl, and 0.05% Tween 20). Next, the filter was incubated (21°C, 1 h) in 1:8,000 dilution of a 1 mg/ml donkey anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody (Amersham) and washed with TBS-T. Immunocomplexes were treated with the enhanced chemiluminescence reagent (ECL; NEN Life Science Products) and visualized by autoradiography.
GSK-3␤ immune complex kinase assay. GSK-3␤ activity was measured by using 100 g of total cellular protein prepared as described in Immunoblotting analysis. The extract was diluted to 400 l with fresh cell lysis buffer and immunoprecipitated with 1 g of the monoclonal anti-GSK-3␤ antibody by rotation for 2 h at 4°C. The immune complexes were isolated by the addition of 25 l of a 50% slurry of protein G-Sepharose and incubation for 1.5 h. Im-munoprecipitates were washed four times in lysis buffer and twice in kinase reaction buffer (8 mM MOPS, pH 7.4, 0.2 mM EDTA, 10 mM magnesium acetate, 1 mM Na 4VO4, 1 mM DTT, 10 g/ml leupeptin, 10 g/ml aprotinin, 0.1 M okadaic acid, and 2 mM Pefabloc SC Plus). Kinase assays were performed in 40 l of total reaction buffer containing 62.5 M phospho-glycogen synthase peptide-2 (Upstate Biotechnology), 20 mM MgCl 2, 125 M ATP, and 10 Ci [␥-32 P]ATP. The reaction mixture was allowed to proceed for 30 min at 30°C with shaking, and 25 l of the supernatant were spotted onto Whatmann P81 phosphocellulose paper. The filter squares were washed five times for 5 min each in 0.75% phosphoric acid. Next, the filters were briefly rinsed in acetone, dried at room temperature, and subjected to liquid scintillation counting. A sample including all assay components except the immunoprecipitate was included in each experiment as a background control.
Statistics. All values are means Ϯ SE. All differences between groups were determined by using either two-tailed Student's t-test or one-way ANOVA. If ANOVA revealed significant effects, Tukey's post hoc test was applied. For all statistical tests, a 0.05 level was used as statistical significance.
RESULTS
Inhibitors of active GSK-3␤ produce hypertrophy of C 2 C 12 myotubes. When LiCl, an inhibitor of GSK-3␤ activity, was included in the culture medium, the area of C 2 C 12 myotubes was 85% greater (Fig. 1) . Inclusion of IGF-I (250 ng/ml), instead of LiCl, in the incubation medium resulted in a similar increase in myotube area (80%). The IGF-I-induced increase in myotube area confirmed the finding of Rommel et al. (12) .
IGF-I produces a transient phosphorylation of GSK-3␤ in C 2 C 12 myotubes. GSK-3␤ phosphorylation was increased 732, 908, 914, and 1,312% after exposure to IGF-I (250 ng/ml) for 15 min, 30 min, 1 h, and 12 h, respectively, in C 2 C 12 myotubes (Fig. 2A) . However, after 24 h of IGF-I exposure, GSK-3␤ phosphorylation returned to baseline levels. These observations extend the single time point (15 min) reported by Rommel et al. (12) and show that the GSK-3␤ phosphorylation effect is transient.
IGF-I suppresses GSK-3␤ activity. GSK-3␤ kinase activity in C 2 C 12 myotubes was decreased by 12-33% at 1 min, 15 min, 30 min, 1 h, 12 h, and 24 h after IGF-I was added to the incubation medium (Fig. 2B) .
IGF-I increases Akt phosphorylation in C 2 C 12 myotubes. Two-, four-, three-, and onefold increases in Akt phosphorylation (Ser 473 ) were detected after C 2 C 12 myotubes were exposed to IGF-I (250 ng/ml) for 15 min, 30 min, 1 h, and 12 h, respectively (Fig. 3A) . After 24 h of IGF-I exposure, Akt phosphorylation returned to baseline levels. These observations extend the single time point (15 min) reported by Rommel et al. (12) and show that the Akt phosphorylation effect is transient. In addition, PI3Ј-kinase inhibitors decreased Akt phosphorylation: LY-294002 (100 M), an inhibitor of PI3Ј-kinase, suppressed IGF-I-induced Akt phosphorylation by 54% in myotubes (Fig. 3B) , and wortmannin (150 M), a different inhibitor of PI3Ј-kinase, inhibited Akt by 56% in the presence of IGF-I.
PI3Ј-kinase inhibitors block GSK-3␤ phosphorylation. LY-294002 (100 M), an inhibitor of PI3Ј-kinase, suppressed IGF-I-induced GSK-3␤ phosphorylation by 67% in myotubes (Fig. 3C) , and wortmannin (150 M), a different inhibitor of PI3Ј-kinase, inhibited GSK-3␤ phosphorylation by 92% in the presence of IGF-I. These results confirm the findings of Rommel et al. (12) .
Constitutively active GSK-3␤ decreases NFAT-inducible reporter gene activity. As a biological probe for the presence of nuclear NFAT, a promoter containing multiple NFAT binding sites driving a firefly luciferase reporter gene, was transfected into myoblasts. To normalize for transfection efficiencies, pRL-null Renilla luciferase was cotransfected (values ranged from 737 to 1,221 relative light units across all conditions). Whereas LiCl had no effect on NFAT-inducible luciferase activity, IGF-I increased luciferase activity by 145% in C 2 C 12 myotubes (Fig. 4) . However, the inclusion of a constitutively active GSK-3␤ (cGSK-3␤A9; Ser 9 mutated to an alanine) with IGF-I reversed the enhancement by IGF-I of NFAT-inducible luciferase activity. Furthermore, the addition of LiCl with IGF-I and cGSK-3␤ rescued the reversal by cGSK-3␤ of IGF-I's stimulation of NFAT-driven luciferase activity. There was no change in NFAT-driven luciferase activity when the medium was supplemented with LiCl compared with the NFAT-only condition. A 190% increase in luciferase activity occurred when myoblasts transfected with the constitutively active pGSK-3␤A9 were exposed to medium supplemented with both IGF-I and LiCl.
DISCUSSION
The purpose of this study was to determine whether GSK-3␤ plays a role in skeletal myotube hypertrophy. Of key significance was the initial finding that noncompetitive inhibition of GSK-3␤ by LiCl was associated with an 85% increase in myotube surface area in culture without an increase in NFAT reporter gene activity. The observation showing an increase in muscle cell size associated with GSK-3␤ inhibition confirms the recent results of Rommel et al. (12) , who used a dominant-negative GSK-3␤ cDNA to produce profound C 2 C 12 myotube hypertrophy. Our findings strongly suggest that GSK-3␤ inhibition, or another pathway activated and/or inhibited by Li ϩ , may be involved in increasing myotube size. LiCl has been widely used to assess the functional role of this enzyme in various contexts (16) . Although the nonspecific effects of LiCl are limited, recent evidence does suggest that it may act as an inhibitor of casein kinase-2, p38 kinase, and mitogen-activated protein kinase kinase-2 (5). However, the LiCl-associated increase in myotube area and other corroborative reports in the literature (6, 12) favor a prohypertrophic mechanism for Li ϩ via inhibition of GSK-3␤ in skeletal myotubes.
These skeletal muscle findings are similar to a recent finding for a critical role for GSK-3␤ as a negative regulator of cardiac hypertrophy in culture and in whole animals (1, 6, 10) . For example, Haq et al. (6) observed that exposure of neonatal cardiomyocytes to LiCl reversed the inhibitory effects of cGSK-3␤ (GSK-3␤A9 mutant) on protein synthesis and sarcomere organization. Also, in cardiac tissue, expression of cGSK-3␤A9 attenuated the myocardial hypertrophy induced by the expression of a constitutively active calcineurin in transgenic mice (1) . Therefore, GSK-3␤ may have a role in hypertrophy of both cardiac and skeletal muscle.
An alternative approach to inhibit GSK-3␤ activity is to apply IGF-I to muscle cells (12) . IGF-I signals the phosphorylation of Akt, which in turn inactivates GSK-3␤ by phosphorylation of Ser 9 (10) . IGF-I has been shown to produce myotube hypertrophy and increase GSK-3␤ phosphorylation (12) . In other cell types the phosphorylation of GSK-3␤ by IGF-I decreases GSK-3␤ activity (7, 11) . We therefore pursued an experiment to test whether the IGF-I-induced reduction of GSK-3␤ kinase activity would be associated with an increase in NFAT-responsive gene activity. The NFATluciferase reporter plasmid selected for these experiments contained four direct repeats of the NFAT binding sequence (Ϫ286 to Ϫ257) from the human interleukin-2 (IL-2) gene. As expected, IGF-I increased the NFAT-responsive reporter gene activity by 145% in Fig. 2 . A: changes in glycogen synthase kinase-3␤ (GSK-3␤) phosphorylation in C2C12 myotubes after exposure to IGF-I (250 ng/ml) for various times, indicated in minute (m) or hours (h). Representative examples of GSK-3␤ (Ser 9 and total) immunoblots are depicted at bottom. B: decreases in GSK-3␤ kinase activity after exposure to IGF-I (250 ng/ml) for various times. Control samples were normalized to 100% and the data are expressed as percent decreases in kinase activity after IGF-I exposure. *Statistical difference from control myotubes at the P Ͻ 0.05 level. Values are means Ϯ SE; n ϭ 3 independent culture dish experiments performed on 3 different days.
C 2 C 12 myotubes (Fig. 4) . Moreover, the increase in NFAT-driven reporter gene was blocked by the simultaneous overexpression of cGSK-3␤A9. Unexpectedly though, LiCl, a noncompetitive inhibitor of GSK-3␤, did not enhance NFAT-inducible luciferase activity but did increase C 2 C 12 myotube area. We interpreted the latter result to suggest that LiCl increases myotube area independently of an enhancement of NFAT-inducible transcriptional activity. Whereas cGSK-3␤ blocked the stimulation by IGF-I of NFAT-responsive luciferase activity, addition of LiCl to this mixture to noncompetitively inhibit GSK-3␤ rescued the stimulation by IGF-I of NFAT-reporter gene activity to a value seen with IGF-I alone. Because LiCl alone did not increase NFAT-responsive reporter gene activity, we infer that IGF-I in the presence of LiCl is able to enhance this NFAT-inducible marker by a GSK-3␤-independent mechanism (Fig. 5) .
GSK-3␤ has been shown to have multiple cellular targets. For example, Harwood (7) recently described GSK-3␤ as a "vital regulatory kinase with a plethora of significant cellular targets, some of which include cytoskeletal and transcription factor proteins." GSK-3␤ is also known to effect protein synthesis by altering the phosphorylation status of the ␣-subunit of the eukaryotic initiation factor eIF-2. More specifically, phosphorylation of Ser 540 on eIF-2␤ by GSK-3␤ results in inhibition of the GDP/GTP exchange activity of eIF-2 and an overall reduction in protein synthesis (11) . Therefore, the effects of inhibition of GSK-3␤ kinase activity could most likely be multifactorial with regard to skeletal muscle hypertrophy.
Our current results regarding the effect of IGF-I on NFAT transcriptional activity differ from those recently published by Rommel et al. (12) . They reported that the addition of 10 ng/ml IGF-I in the culture medium of C 2 C 12 myotubes, 48 h postdifferentiation, resulted in a cytoplasmic localization of inactivated B: inhibition of Akt phosphorylation with pharmacological inhibitors of phosphatidylinositol 3'-kinase (PI3Ј-kinase) activity in C2C12 myotubes after exposure to IGF-I (250 ng/ml). Akt expression was calculated in the same manner as described in A. Representative Akt (Ser 473 and total) immunoblots are depicted at bottom. C, control (myotubes not receiving any inhibitors); LY, myotubes receiving LY-294002 (100 M); W, myotubes receiving wortmannin (150 M). *Statistical difference from control at the P Ͻ 0.05 level; #statistical difference from IGF-I at the P Ͻ 0.05 level. C: inhibition of GSK-3␤ phosphorylation with pharmacological inhibitors of PI3Ј-kinase activity in C2C12 myotubes after exposure to IGF-I (250 ng/ml). GSK-3␤ expression was calculated in the same manner as described in Fig. 2 . Representative examples of GSK-3␤ (Ser 9 and total) immunoblots are also shown. *Statistical difference from all conditions at the P Ͻ 0.05 level; †statistical difference from control at the P Ͻ 0.05 level; #statistical difference from LY and control at the P Ͻ 0.05 level. In A-C, values are means Ϯ SE; n ϭ 3 independent culture dish experiments performed on 3 different days.
NFATc1. In contrast, we observed an increase in NFAT-induced transcriptional activity following the addition of 250 ng/ml IGF-I to C 2 C 12 myoblasts, concurrent with cell transfer into DM. Our observation thus agrees with the findings of Semsarian et al. (14) .
While the reasons for this discrepancy between our report and that of Rommel et al. (12) remain unclear, plausible explanations point to the differences in IGF-I concentration and time point of growth factor exposure. Semsarian and colleagues (13, 14) observed Fig. 4 . Changes in NFAT (nuclear factors of activated T cells)-driven luciferase activity after exposure to IGF-I or LiCl in differential medium. A: all data are expressed as the ratio of NFAT firefly luciferase values to control plasmid Renilla luciferase values. ϩIGF-I, myotubes exposed to IGF-I (250 ng/ml); ϩcGSK, myoblasts transfected with constituently active mutant pGSK-3␤A9; ϩLiCl; myoblasts exposed to LiCl (100 M). *Statistical difference from all groups except IGF-I ϩ cGSK ϩ LiCl at the P Ͻ 0.05 level. #Statistical difference from all groups except ϩIGF-I at the P Ͻ 0.05 level. Values are means Ϯ SE; n ϭ 6 independent culture dish experiments performed on 3 different days. B: schematic of results shown in A. During the experiments depicted in A, all conditions contained NFAT promoter-luciferase reporter construct (NFAT-Luc). Differential media conditions were as follows: control, 2% horse serum (HS) only; IGF-I, 2% HS and 250 ng/ml IGF-I; cGSK, constitutively active GSK-3␤; LiCl, 10 mM LiCl. 7, no change; 1, increase. (1, 6, 10, 12) were used to construct this drawing. Increased concentrations of IGF-I induced elevations in PI3Ј-kinase activity. A substrate for PI3Ј-kinase is Akt, which PI3Ј-kinase phosphorylates on Ser 473 , inducing an increase in Akt kinase activity. This elevation in Akt kinase activity can then actively phosphorylate GSK-3␤ on Ser 9 , thereby inhibiting GSK-3␤ activity. This reduction in GSK-3␤ activity allows NFAT to remain in the nucleus for a longer period of time, thereby promoting increased activation of hypertrophic genes. Solid arrows indicate the proposed action of IGF-I signaling proteins, whereas dotted arrows indicate the directional change in response to IGF-I. C 2 C 12 hypertrophy following the addition of 250 ng/ml IGF-I to the cell medium before or at the time of myoblast differentiation into postmitotic skeletal myotubes. Importantly, myotube hypertrophy was not noted if IGF-I was introduced at a concentration of 25 ng/ml or at additional time points beyond 24 h postdifferentiation (13) . Therefore, although our methods mimicked those of Semsarian et al., who found myotube hypertrophy and NFATc1 accumulation in the nucleus at our chosen IGF-I concentration (250 ng/ml), the study of Rommel et al. (12) employed an IGF-I dosage (10 ng/ml) and time point of exposure previously shown by Semsarian et al. (13) to be ineffective in producing myotube hypertrophy. Furthermore, the NFAT-luciferase reporter assay system used in our study allows the direct measure of the transcriptional activity of various activated NFAT isoproteins. Crabtree (4) indicates that, because of the unusual NFAT-DNA binding domain, NFAT exhibits weak DNA binding and requires an unknown nuclear partner for tight association with DNA. Therefore, our utilization of an NFAT-driven reporter construct allows a direct biological measure of nuclear NFAT-inducible activity by IGF-I. In addition, Rommel et al. (12) reported the phosphorylation status and the cytoplasmic or nuclear location of only one isoform, NFATc1. There is recent evidence indicating that NFAT isoforms NFATc2 (8) and NFATc3 (9) play important roles in the control of skeletal muscle size and myogenesis, respectively, which strongly suggests that NFATc1 is not the only member of this family of transcription factors involved in the regulation of myotube hypertrophy. We therefore conclude that IGF-I increases NFAT-inducible activity.
To determine how IGF-I signals GSK-3␤ phosphorylation in our cells, further experiments were performed in C 2 C 12 myotubes. Rommel et al. (12) suggested that IGF-I-induced phosphorylation of GSK-3␤ occurs due to activation of the PI3Ј-kinase/Akt pathway. Here, we confirm and extend their report of increased GSK-3␤ phosphorylation by our observation that the kinase activity of GSK-3␤ is also inhibited by IGF-I (Fig. 3B) . Taken together, these observations strongly suggest that PI3Ј-kinase and Akt are upstream mediators of the IGF-I-mediated phosphorylation of GSK-3␤ in skeletal myotubes.
In summary, our results indicate that phosphorylation-mediated inhibition of GSK-3␤ via the PI3Ј-kinase/Akt cascade could play an important regulatory role in skeletal myotube hypertrophy. Noncompetitive deactivation of GSK-3␤ by LiCl resulted in a marked increase in skeletal myotube area without activating NFAT-inducible luciferase activity. The IGF-I-increased NFAT-inducible reporter gene activity was prevented by constitutive activation of GSK-3␤. However, NFAT reporter gene activity was increased when IGF-I was placed together with LiCl and a constitutively active GSK-3␤. These data show that IGF-I can produce increases in NFAT-inducible transcriptional activity independently of GSK-3␤. Taken together, these data suggest that a dose of 250 ng/ml IGF-I does, in fact, induce NFAT transcriptional activity and that this increase in transcriptional activity can be attenuated by GSK-3␤. Finally, our data and that of Rommel et al. (12) clearly indicate that GSK-3␤ can play an important regulatory role in modulating skeletal myotube size.
